Clinicians are increasingly faced with a familiar question: how much visual function are we prepared to sacrifice in pursuit of better myopia control?
A new systematic review and meta-analysis published in Ophthalmic and Physiological Optics has sought to evaluate the accommodative amplitude and binocular visual function effects of varying concentrations of atropine when used for myopia control in children and adolescents. Examining data from 13 randomized controlled trials, the authors found that atropine's effects on accommodation and binocular vision are clearly dose dependent.
The review evaluated atropine concentrations ranging from 0.01% to 1%, focusing on accommodative amplitude as the primary outcome and assessing additional binocular vision parameters including accommodative lag, stereoacuity, heterophoria, and fusional vergence. The results reveal a distinct concentration-response relationship.
At the lowest concentration studied, 0.01%, atropine produced only a small reduction in accommodative amplitude, averaging less than one diopter. Importantly, the effect was inconsistent across studies and follow-up periods, and there was no significant impact on accommodative lag, stereoacuity, or most binocular vision measures. These findings reinforce the perception of 0.01% atropine as a functionally safe intervention, particularly for children engaged in prolonged near work.
The picture changes at higher concentrations. Intermediate doses of 0.02–0.03% showed variable effects, suggesting a transition zone where accommodative impairment begins to emerge in some patients but remains unpredictable. By contrast, 0.05% atropine demonstrated a consistent and clinically meaningful reduction in accommodative amplitude, with effects appearing within days of treatment initiation and persisting for years in long-term studies. Changes in binocular vision – including shifts in near heterophoria and reductions in negative fusional vergence – were also observed.
For concentrations of 0.1% and above, the impact was dramatic. Accommodation losses exceeded 9 diopters on average, reflecting the strong cycloplegic action long associated with higher-dose atropine therapy.
The findings arrive at a particularly relevant moment for myopia management. Recent evidence, including outcomes from the Low-Concentration Atropine for Myopia (LAMP) study, has encouraged a move toward 0.05% atropine because of its superior efficacy in slowing axial elongation. Yet the new analysis highlights that greater efficacy comes with measurable functional costs.
The challenge for clinicians, therefore, is not simply choosing the most effective concentration, but balancing efficacy against quality of vision. A reduction of around two diopters in accommodative amplitude may be clinically insignificant for some children, while others may experience symptoms of near blur, eyestrain, or difficulties with sustained reading and screen use.
The authors argue that accommodation and binocular vision assessments should play a larger role in routine atropine prescribing, particularly when using concentrations of 0.05% or higher. Monitoring near visual performance, discussing potential symptoms with patients and parents, and considering interventions such as near additions when required may help to optimize outcomes.
Ultimately, the study reinforces a central principle of modern myopia management: there is no universally ideal atropine dose. Instead, treatment should be individualized, balancing the need for myopia control against the preservation of comfortable, functional long-term vision.
